First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
Michael L. Maitland(Virginia Cancer Institute), Emiliano Calvo(South Texas Accelerated Research Therapeutics), Shivaani Kummar(Oregon Health & Science University), Víctor Moreno, Michelle Bowers(Pfizer (United States)), Valentina Boni, Xiaohua Xin(Pfizer (United States)), Erica Stringer-Reasor(University of Alabama at Birmingham), Jasgit C. Sachdev(HonorHealth), Allison Moreau(Pfizer (United States)), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Amy Jackson-Fisher(Yale University), Ray Li(Pfizer (United States)), Manish Sharma(University of Chicago), Dawei Xuan(Pfizer (United States)), Shilpa Alekar(Pfizer (United States)), Eric L. Powell(Pfizer (United States)), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics)
Cited by 81
Related Papers
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
|The Lancet Oncology|2016|1.3k
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590